I do have only one simple question. How many people took advantage from the 
fact Nonmem was distributed as open source? If we are talking about a very 
small percentage, is this discussion worthwhile? How many people except bob 
bauer and may be somebody else I am not aware of are able to follow and 
understand the cuirrent nonmem code?
Serge

________________________________

From: [email protected] 
To: Ludden, Thomas ; [email protected] 
Sent: Thu Jul 02 23:46:09 2009
Subject: [NMusers] RE: NONMEM 7 Update 


 

Thomas

 

Didn't ICON consider that indeed, this decision might stimulate the divergence 
of an open-source clade of NONMEM, somewhat like R stemmed out of S-plus? If a 
small academic group starts to work in that direction, it would certainly be 
quickly joined by many…

 

Thierry Buclin

Univ. Hospital, Lausanne

 

De : [email protected] [mailto:[email protected]] De la 
part de Ludden, Thomas
Envoyé : jeudi, 2. juillet 2009 15:15
À : Eleveld, DJ; [email protected]
Cc : Krohn, Anthony
Objet : RE: [NMusers] NONMEM 7 Update

 

Dear All:

        Icon Development Solutions has invested in the further development of 
NONMEM.  By mutual agreement with the University of California at San 
Francisco, NONMEM 7 is intellectual property belonging to IDS.  However, IDS 
will continue to pay royalties to UCSF.  

         

        The business plan under which NONMEM 7 was developed calls for the 
protection of the I.P. involved.  In addition, NONMEM 7 contains several 
updated routines developed and owned by IMSL (Visual Numerics Inc.).  Our 
agreement with IMSL stipulates that we will not distribute their source code. 
The installer will compile the software but will not allow the unencrypted 
source code to remain on the users computer.  The licensing agreement will also 
stipulate that any attempt to access the source code will be a violation of the 
agreement.

         

        Some source code will be left unencrypted for various reasons, one 
being the need for users to change certain values in SIZES and perhaps other 
resource routines.

        Tom 

        Thomas M. Ludden Ph.D.
        Vice-President, Pharmacometrics R&D
        ICON Development Solutions 

        Tel: + 1 410 696 3040
        Mob: + 1  410 258 2411
        Fax:  + 1 410 480 0776
        Email: [email protected]

        Web: www.icondevsolutions.com 


-- 
The information contained in this email message may 
contain confidential or legally privileged information and is intended solely 
for the use of the named recipient(s).  No confidentiality or privilege is 
waived or lost by any transmission error. If the reader of this message is 
not the intended recipient, please immediately delete the e-mail and all 
copies of it from your system, destroy any hard copies of it and notify the 
sender either by telephone or return e-mail.  Any direct or indirect use, 
disclosure, distribution, printing, or copying of any part of this message is 
prohibited.  Any views expressed in this message are those of the individual 
sender, except where the message states otherwise and the sender is 
authorized to state them to be the views of XOMA.

Reply via email to